Results 1 to 10 of about 2,551 (122)

Formulation self nano emulsifying drug delivery system glimepiride using oleic acid as oil phase [PDF]

Pharmaciana, 2017
Glimepiride is a third generation sulphonylurea antidiabetic drug. Glimepiride is poorly water soluble drug that may cause poor dissolution and unpredicted bioavailability.
Sani Ega Priani, Nurrayyan, Fitrianti Darusman   +2 more
doaj   +3 more sources

Identification of the Glimepiride and Metformin Hydrochloride Physical Interaction in Binary Systems

Borneo Journal of Pharmacy, 2021
Glimepiride is often combined with metformin HCl as an oral antidiabetic in type II diabetes mellitus, which provides a complementary and synergistic effect with multiple targets for insulin secretion.
Fitrianti Darusman, Taufik Muhammad Fakih, Gina Fuji Nurfarida   +2 more
doaj   +2 more sources

Interaction of glimepiride with prokinetic drugs on some of gastrointestinal functions in STZ-induced diabetic mice [PDF]

Bulletin of Faculty of Pharmacy Cairo University, 2013
Aim: To investigate the effects of metoclopramide, domperidone and erythromycin on blood glucose and serum insulin levels, gastrointestinal motility and carbohydrate absorption in streptozotocin-induced diabetic mice treated with glimepiride.
Mohamed A. Fouad, Hekma A. Abd El latif, Mostafa E. El Sayed   +2 more
doaj   +2 more sources

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundSulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ ...
Kyeong Won Lee, Yun Hyi Ku, Min Kim, Byung Yong Ahn, Sung Soo Chung, Kyong Soo Park   +5 more
doaj   +1 more source

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study [PDF]

Diabetes & Metabolism Journal, 2020
BackgroundThere is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy.
Jeong Mi Kim, Sang Soo Kim, Jong Ho Kim, Mi Kyung Kim, Tae Nyun Kim, Soon Hee Lee, Chang Won Lee, Ja Young Park, Eun Sook Kim, Kwang Jae Lee, Young Sik Choi, Duk Kyu Kim, In Joo Kim   +12 more
doaj   +1 more source

Comparative Efficacy of Metformin and Glimepiride in Modulating Pharmacological Network to Increase BDNF Levels and Benefit Type 2 Diabetes-Related Cognitive Impairment

Biomedicines, 2023
Cognitive impairment is anotable complication of type 2 diabetes (T2DM), accompanied by reduced brain-derived neurotrophic factor (BDNF) in the brain and blood.
Athira Anirudhan, Sheikh F. Ahmad, Talha Bin Emran, Paola Isabel Angulo-Bejarano, Ashutosh Sharma, Shiek S. S. J. Ahmed   +5 more
doaj   +1 more source

Food-drug interaction and pharmacokinetic study between fruit extract of Capsicum frutescens L. and glimepiride in diabetic rats

Clinical Phytoscience, 2020
Background The present study was designed to explore the food-drug and pharmacokinetic interaction between C.frutescens, a culinary herb on hypoglycemic activity of glimepiride, a sulfonyl urea derivative used in the treatment of type-2 diabetes) in ...
Mettupalayam Annadurai Raja, Prasenjit Mondal, Kola Venu, Manish Kumar Thimmaraju, Poudala Kiran   +4 more
doaj   +1 more source

Glimepiride Treatment Upon Reperfusion Limits Infarct Size via the phosphatidylinositol 3-Kinase/Akt Pathway in Rabbit Hearts

Journal of Pharmacological Sciences, 2009
The phenomenon termed postconditioning, that is, brief episodes of ischemia/reperfusion at the onset of reperfusion reduce infarct size, is thought to involve the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway.
Hirofumi Nishida, Toshiaki Sato, Momoko Nomura, Masaru Miyazaki, Haruaki Nakaya   +4 more
doaj   +1 more source

Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.

PLoS ONE, 2022
Patients with type 2 diabetes who have cardiovascular disease and are receiving empagliflozin have a lower rate of primary composite cardiovascular outcomes.
Haruka Tamura, Yoshinobu Kondo, Kohei Ito, Masanori Hasebe, Shinobu Satoh, Yasuo Terauchi   +5 more
doaj   +1 more source

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

Endocrine Connections, 2017
Objective: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study).
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev   +4 more
doaj   +1 more source